10 October 2021 | Sunday | News
The 6,000 square-meter site will provide flexible clinical supply solutions, serving both local and global biotech and pharmaceutical companies. The facility, one of the largest of its kind in Japan, will play an important role in Catalent’s expanding Asia-Pacific network, working alongside two sites in China and one in Singapore to ensure customers’ clinical trials are well-served across the region.
“Shiga will become a key hub in our Asia-Pacific Clinical Supply Services network, with Japan now representing the third-largest clinical trials market in the world,” commented Roel de Nobel, Vice President and General Manager of Asia Pacific, Catalent Clinical Supply Services. He added, “The new site builds upon Catalent’s 40 years of in-country presence, and in addition to bi-lingual English and Japanese project and clinical supply management, will provide primary and secondary packaging and labeling, storage and distribution, cold chain handling, and in-country returns and destruction services.”
Acquired from Teva-Takeda Pharmaceuticals in July 2020, the Shiga site has since undergone significant redevelopment to optimize Catalent’s service offering, and it will also add specialized solutions for the Asia-Pacific markets including Catalent’s FastChain® demand-led supply, white glove handling and logistics.
With sites in the U.S., U.K., Germany, Singapore, Japan and China, and an extended network of over 50 depots, Catalent’s clinical supply services can handle a broad range of international compliance and distribution requirements to support global clinical trials.